Catalogo de Investigaciones 2018-2019

144 FACULTAD Seeking new target candidates in cancer: Analysis of the correlation of Oncogene expression with Drug activity The World Health Organization (WHO) has identified cancer as the world’s second-largest cause of death. Despite the significant progress over recent years, drug resistance remains a biomedical challenge. Thus, the development of new strategies to find new drug candidates for therapy is key to providing a fighting chance for cancer patients. Using the Cancer Gene Census from COSMIC and the drug activity-expression data derived from CellMiner, we analyzed 705 cancer genes and over 21,000 compounds to discover new plausible interactions between drugs and oncogenes. Bioinformatic analyses were performed to calculate the Pearson and Spearman correlations between the gene expression profiles in 60 cancer cell lines and the expression profiles when treated with different drugs. We focused on FDA-approved cancer drugs, and explored other molecules when they reported very significant correlations. Based on the activity-expression patterns between FDA-approved drugs and their known drug targets (i.e., their gene targets), we propose repurposing some of these drugs in the treatment of other types of cancers. We also identified new potential drug candidates for the treatment of cancer. Our analysis presents several molecules as prospective drugs for expanding chemotherapeutic therapy. dra. mónica m. arroyo departamento de química, pucpr bioinformatics and functional genomics group, cancer research center (cic-imbcc, csic/usal/ibsal), consejo superior de investigaciones científicas (csic) and university of salamanca (usal), salamanca, españa alberto berral-gonzález diego alonso-lópez javier de las rivas bioinformatics and functional genomics group, cancer research center (cic-imbcc, csic/usal/ibsal), consejo superior de investigaciones científicas (csic) and university of salamanca (usal), salamanca, españa pharmacogenomics drug target transcriptomics drug activity cancer drug